Clinical Trials Logo

Primary Plasma Cell Leukemia clinical trials

View clinical trials related to Primary Plasma Cell Leukemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT06333509 Not yet recruiting - Multiple Myeloma Clinical Trials

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Start date: April 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.

NCT ID: NCT06140966 Recruiting - Multiple Myeloma Clinical Trials

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Start date: October 20, 2023
Phase: Phase 2
Study type: Interventional

This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma

NCT ID: NCT05838131 Recruiting - Multiple Myeloma Clinical Trials

Study of CT071 Injection in RRMM or PPCL

Start date: April 28, 2023
Phase: Early Phase 1
Study type: Interventional

A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

NCT ID: NCT01553357 Completed - Clinical trials for Primary Plasma Cell Leukemia

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Start date: March 2009
Phase: Phase 2
Study type: Interventional

This is an open label, multicenter, exploratory, single arm, two-stage study aiming to explore efficacy and safety of lenalidomide and dexamethasone combination (LD) as first line therapy in previously untreated patients with primary Plasma Cell leukemia (PPCL).